Associate Director, Clinical Trial Start-Up
Jazz Pharmaceuticals
Summary
The Associate Director, Study Start Up Strategy, provides advanced expertise in clinical trial start-up processes, responsible for developing and overseeing global clinical trial start-up (CTSU) strategies across the Jazz clinical trial portfolio. This role combines operational leadership with strong cross-functional collaboration, CRO oversight, and continuous improvement, ensuring compliance with global regulatory and quality standards. This individual leverages analytics and data-driven insights—both historical and predictive—to strategically inform country and site activation plans, optimize protocol implementation for start-up efficiency, and mitigate operational risks.
Job description
Essential Functions/Responsibilities
- Lead or provide oversight of development and execution of study-level start-up strategies, country/site activation plans, and risk mitigation approaches through SSU roles and/or CRO.
- Develop site activation projections and provide input into study timeline development through data-driven assessment of country requirements, historical timelines and leveraging predictive data and emerging technologies.
- Serve as a Subject Matter Expert (SME) in global study, country, and site start-up pathways, offering strategic guidance to internal teams and partners and in relevant industry discussions.
- Partner cross-functionally to deliver start-up insights and strategies that inform country and site selection, timelines, and country/site activation strategies, aligning these with protocol requirements at the indication, program, or study level through collaborative workstreams and representation on the Clinical Trial Working Group (CTWG) for assigned trials.
- Track and analyze SSU performance metrics, proactively identifying trends, issues at study, country, program level, working cross functionally to address and communicate risks.
- Leverage historical and predictive data, real-world evidence, and emerging technologies to optimize start-up strategies, mitigate operational risks, and enhance country and site activation processes.
- Oversee SSU team members, providing guidance, training, and performance feedback to support their development.
- Oversight of CROs/vendors executing start-up activities, including performance tracking against KPIs and timelines and provides support for governance activities.
- Lead or contribute to functional initiatives that improve start-up methodology, quality, tools, and process efficiency across programs, including the development and implementation of SSU policies, processes, and training.
- Support audit and inspection readiness by ensuring accurate and complete documentation of start-up activities and regulatory submissions.
- Participate in the development and refinement of global SSU policies, SOPs, and training curricula aligned with evolving regulatory and business needs.
- Represent SSU in relevant industry discussions, cross-industry collaboration efforts, and internal governance meetings as appropriate.
Required Knowledge, Skills, and Abilities
- Recognized as a subject matter expert in clinical site start-up with strong operational understanding of global regulatory requirements, IRB/EC processes, and site activation pathways.
- Proven ability to drive cross-functional decision-making through data-driven insights.
- Demonstrated success supporting or leading global clinical start-up strategy in both in-house and outsourced models, specifically oversight of CROs or vendors.
- Experience leveraging digital technologies to inform study planning and start-up optimization.
- Ability to analyze complex issues and apply strategic thinking to identify risk and resolve operational challenges across cross-functional settings.
- Strong leadership, collaboration, and communication skills, with the ability to influence cross-functional teams and external partners.
- Proficiency with CTMS, document management systems, and SSU technology platforms (e.g., Veeva Vault), with experience in assessment or utilization of AI in this SSU space preferred.
- Experience contributing to inspection readiness and continuous process improvement initiatives.
- 10% to 20% travel, US and International.
Required/Preferred Education and Licenses
- Bachelor’s degree in life sciences or related field required; advanced degree preferred.
- 8-10 years of experience in clinical research, with at least 5 years focused on clinical trial start up or site activation.
Requirements
- Bachelor’s degree in life sciences or related field required; advanced degree preferred.
- 8-10 years of experience in clinical research, with at least 5 years focused on clinical trial start up or site activation.
- Recognized as a subject matter expert in clinical site start-up with strong operational understanding of global regulatory requirements, IRB/EC processes, and site activation pathways.
- Proven ability to drive cross-functional decision-making through data-driven insights.
- Demonstrated success supporting or leading global clinical start-up strategy in both in-house and outsourced models, specifically oversight of CROs or vendors.
- Experience leveraging digital technologies to inform study planning and start-up optimization.
- Ability to analyze complex issues and apply strategic thinking to identify risk and resolve operational challenges across cross-functional settings.
- Strong leadership, collaboration, and communication skills, with the ability to influence cross-functional teams and external partners.
- Proficiency with CTMS, document management systems, and SSU technology platforms (e.g., Veeva Vault), with experience in assessment or utilization of AI in this SSU space preferred.
- Experience contributing to inspection readiness and continuous process improvement initiatives.
- 10% to 20% travel, US and International.
Benefits
- Medical, Dental & Vision
- 401(k) Retirement Savings Plan
- Flexible Paid Vacation
- Annual Cash Bonus
- Incentive Compensation
- Discretionary Equity Grants
Company overview
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company headquartered in Dublin, Ireland, with significant operations in the United States and Europe. Founded in 2003 in California, the company specializes in developing and commercializing innovative medicines for patients with serious diseases, with a primary focus on oncology and neuroscience. Jazz Pharmaceuticals is renowned for its flagship product Xyrem (sodium oxybate), which treats excessive daytime sleepiness and cataplexy in narcolepsy patients, generating substantial revenue for the company. The company's portfolio also includes treatments for epilepsy, sleep disorders, hematology, and oncology, with notable products such as Erwinaze, Defitelio, FazaClo, and Vyxeos. Through strategic acquisitions including GW Pharmaceuticals in 2021, Jazz expanded its neuroscience portfolio with cannabis-based medicines like Epidiolex for severe epilepsy syndromes. With approximately 2,800 employees worldwide and operations across multiple continents, Jazz Pharmaceuticals maintains a strong commitment to research and development, focusing on transforming biopharmaceutical discoveries into novel therapies for patients with limited treatment options. The company operates manufacturing facilities in Ireland, England, and Italy, and continues to pursue innovative approaches to address critical unmet medical needs in specialized therapeutic areas.